View Pages
Regeneron CEO Leonard Schleifer on how the Constitution fuels innovation
Schleifer discusses how 250-year-old constitutional patent protections helped enable generations of American scientific innovation.
Editorial companion
What stands out
Leonard Schleifer spent a CNBC Television interview reminding viewers that America’s constitutional patent protections, written 250 years ago, are the scaffolding under modern biotech. For Regeneron Pharmaceuticals, that legal foundation is not nostalgia, it is business: patents convert risky decades of lab work into time-limited commercial exclusivity that funds more research. It is a useful reminder for investors that a CEO can talk about civic principles and also be signaling why durable intellectual-property protection matters to enterprise value.